Seasonal Affective Disorder (SAD) is a type of depression that occurs during a particular season, usually during the winter months when there is less sunlight. It is estimated that up to 10% of the population in the United States may be affected by SAD. With increasing awareness and diagnosis of SAD, the market for products and treatments that address this condition has been growing steadily. Patients suffering from SAD often seek treatments that can help alleviate these symptoms. The most common treatments for SAD include light therapy, antidepressant medication, and counseling. The demand for these treatments is likely to continue to grow as more people become aware of SAD and seek treatment.
The demand for Seasonal Affective Disorder Market and products is driven by the prevalence of the condition and the desire of patients to alleviate their symptoms. According to the National Institute of Mental Health, SAD is four times more common in women than in men, and it is most prevalent in young adults. The symptoms of SAD can range from mild to severe and can include feelings of sadness, fatigue, loss of interest in activities, and changes in sleep and appetite. The SAD market includes a range of products and treatments that are designed to alleviate the symptoms of the condition. The market can be divided into several segments, including light therapy, medication, counseling, and alternative therapies.
Light therapy is the most commonly used treatment for SAD. It involves exposing the patient to bright light for a set period each day, typically in the morning. The light is usually provided by a lightbox, which emits bright light that simulates natural sunlight. The lightbox market has been growing steadily as more people become aware of the benefits of light therapy. Antidepressant medication is another commonly used treatment for SAD. Medications such as selective serotonin reuptake inhibitors (SSRIs) and bupropion have been shown to be effective in alleviating the symptoms of SAD. The market for antidepressant medication is well-established and is expected to continue to grow as more people seek treatment for SAD.
Read more @ https://creativeedge16.blogspot.com/2023/03/seasonal-affective-disorder-market_21.html
Seasonal Affective Disorder Market information: by type (fall and winter SAD, and others), by diagnosis (physical exam, lab tests, and others), by treatment (light therapy, medications, and others), by end user- global forecast till 2027Market Analysis The global seasonal affective disorder market is predicted to touch USD 694.9 million at a 4.2% CAGR by 2023, as per the latest Market Research Future (MRFR) report.
Based on type, the seasonal affective disorder market is segmented into spring and summer SAD, fall and winter SAD, and others.
The psychological evaluation segment is again segmented into direct observation tests, vocational tests, neuropsychological tests, aptitude tests, achievement tests, attitude tests, personality tests, and intelligence tests.
Regional Analysis By region, the seasonal affective disorder market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA).
This is owing to growing awareness, changing lifestyle, availability of products and treatments, and developing health facilities.
This is owing to limited access to healthcare facilities, less awareness about seasonal affective disorder, and low prevalence rate.
Market HighlightsThe global seasonal affective disorder market is growing moderately, and it is expected to grow at the same pace over the forecast period 2017-2018.
Adoption of advanced diagnosis and treatment also plays an important role in the growth of this market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/4123The global market of seasonal affective disorder was around USD 521.0 million in 2016 and is expected to reach USD 694.9 million by 2023 at a projected CAGR of 4.2%.Major Players in Seasonal Affective Disorder MarketSome of the key market players: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)Regional AnalysisThe global seasonal affective disorder market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & AfricaThe Americas dominate this market, particularly North America due to increasing prevalence of this disorder in the region.
It is estimated that around 10 million Americans are affected by this disorder.
Growing awareness in South American population regarding this disorder is major driving force.Increasing cases of seasonal affective disorder in Europe is leading the market growth.
However, increasing healthcare expenditure, growing awareness, and increasing government support to improve life of patients drive this market.The Middle East & Africa region is expected to have the least growth during the forecast period due to lack of awareness about this disorder and limited access to healthcare facilities.SegmentationThe global seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.On the basis of diagnosis, the market is segmented into physical exam, lab tests, psychological evaluation, and others.
Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others.
Seasonal depression doesn't usually work this way, but with the news that Audi is removing one of its few convertibles from the lineup, there's nothing wrong with getting a little weepy in the middle of summer.
Audi will discontinue its A3 Cabriolet after the 2019 model year, Car and Driver reports.
It's not bringing the executioner's ax down on every A3 variant, just the drop-top, so A3 sedan fans don't have anything to worry about for the 2020 model year.
Thankfully, you can still scoop up one of the 2019 models while they're at dealers.
Each of the A3 Cabriolet's three trims can be had with one of two powertrains.
The base 2.0-liter I4 puts out 184 horsepower and 222 pound-feet of torque, and it comes mated to a seven-speed dual-clutch automatic transmission and front-wheel drive.
